Arda Therapeutics
Austin, US · Founded 2021 · Delaware corporation · 21 employees on LinkedIn · 17 known investors
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases. The company combines drug development expertise with cellular biology to create new therapeutic approaches.
Also known as Arda · ArdaTx
Founders & leadership
Arda Therapeutics was founded in 2021 by Adam Freund and Remi-Martin Laberge.
Board
Investors · 17
__Twitter.png)
Also in the syndicate · 7
Reported raises · per SEC filings
Form D private placements$50.8M disclosed across 2 rounds · 2021–2024
▶$43.3MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
- Vineeta AgarwalaDirector
- Adam FreundExecutive Officer, Director
- Offering amount
- $43.4M
- Amount sold
- $43.3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$7.5MraisedJan 2022 · 10 investors · BiotechnologyRule 506(b)
- Adam FreundExecutive Officer, Director
- Offering amount
- $8.5M
- Amount sold
- $7.5M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Arda Therapeutics is a biotechnology company developing therapies aimed at chronic diseases by eliminating the pathogenic cells that drive them. Its stated approach begins with single-cell data, which it uses to identify which cell populations are pathogenic and to determine how those cells can be targeted.
The company then designs therapies intended to eliminate those specific cells while sparing others, framing cells as both the functional units of life and of disease.
▸Full profile — market position, technology
Market position
Arda operates in therapeutics for chronic disease, with a cell-elimination approach rather than a conventional pathway- or symptom-directed strategy.
Technology
Arda's platform is built on single-cell data analysis, used first to identify pathogenic cell populations and the targeting handles that distinguish them, and then to design therapies that selectively eliminate those cells and only those cells.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 6
by search overlap
Companies competing with Arda Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Legal entities · 1
corporate structureIn the news
▸Research sources · 1
primary sources listed
- Arda Therapeuticsardatx.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Arda Therapeutics do?
- Arda Therapeutics uses single-cell data to design therapies that eliminate the pathogenic cells driving chronic diseases.
- Who founded Arda Therapeutics?
- Arda Therapeutics was founded by Adam Freund, Remi-Martin Laberge in 2021.
- Who are Arda Therapeutics's investors?
- Arda Therapeutics's investors include age1, Andreessen Horowitz, Strawberry Creek Ventures, Alumni Ventures, Gaingels, GV (Google Ventures), Indicator Ventures, Mana Ventures and 2 more.
- How much funding has Arda Therapeutics raised?
- Arda Therapeutics has disclosed $50.8M raised across 2 rounds.
- Where is Arda Therapeutics headquartered?
- Arda Therapeutics is headquartered in Austin, US.